Q4 2025 · 13F-HR
Vitruvian Partners LLPholdings as filed
Filed 2026-02-06 · accession 0001420506-26-000200
$139.2M
Reported value
7
Positions
2025-12-31
Period end
The Brief · Vitruvian Partners LLP · Q4 2025
AI · grounded in 13F
Vitruvian Partners LLP increased its position in GLBE by 21.9%. The fund also accumulated shares of RXST by 20.85%. Conversely, the firm trimmed its holding in XMTR by 18.56%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 433313103 | HNGE | HINGE HEALTH INC | $58.1M | 41.7% | 1,250,000 | Common | SOLE |
| 57142B104 | MQ | MARQETA | $32.6M | 23.4% | 6,853,183 | Common | SOLE |
| 141788109 | CARG | CARGURUS INC | $18.1M | 13.0% | 472,959 | Common | SOLE |
| 98423F109 | XMTR | XOMETRY INC | $11.4M | 8.20% | 191,919 | Common | SOLE |
| M5216V106 | GLBE | GLOBAL-E | $8.3M | 5.94% | 210,209 | Common | SOLE |
| 57777K106 | MXCT | MAXCYTE | $7.8M | 5.62% | 5,043,356 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT | $2.9M | 2.09% | 278,865 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.